Kupfer, Stuart

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 2,502

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial

Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 850

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 757

Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

Wilcox, R., Bousser, M.-G., Betteridge, D. J., Schernthaner, G., Pirags, V., Kupfer, S., & Dormandy, J. (2007) · Stroke

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 475

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Zannad, F., Garcia, A. A., Anker, S. D., Armstrong, P. W., Calvo, G., Cleland, J. G. F., Cohn, J. N., Dickstein, K., Domanski, M. J., Ekman, I., et al. (2013) · European Journal of Heart Failure

Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 231

Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension

White, W. B., Weber, M. A., Sica, D., Bakris, G. L., Perez, A., Cao, C., & Kupfer, S. (2011) · Hypertension

Blood Pressure and Hypertension StudiesRenin-Angiotensin System Studies

Cited by 216

The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure

Bakris, G. L., Sica, D., Weber, M., White, W. B., Roberts, A., Perez, A., Cao, C., & Kupfer, S. (2011) · The Journal of Clinical Hypertension

Blood Pressure and Hypertension StudiesRenin-Angiotensin System Studies

Cited by 143

Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil

Bakris, G. L., Sica, D., White, W. B., Cushman, W. C., Weber, M. A., Handley, A., Song, E., & Kupfer, S. (2012) · The American Journal of Medicine

Blood Pressure and Hypertension StudiesRenin-Angiotensin System Studies

Cited by 90

A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in Patients Treated With a Calcium Antagonist Versus an Atenolol Hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST)

Ried, L. D., Tueth, M. J., Handberg, E., Kupfer, S., & Pepine, C. J. (2005) · Psychosomatic Medicine

Blood Pressure and Hypertension StudiesCardiac Health and Mental Health

Cited by 63

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril

Bönner, G., Bakris, G. L., Sica, D., Weber, M. A., White, W. B., Perez, A., Cao, C., Handley, A., & Kupfer, S. (2013) · Journal of Human Hypertension

Blood Pressure and Hypertension StudiesRenin-Angiotensin System Studies

Cited by 61